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Reduction of
Nephrotoxicity Associated
with Amphotericin B
Deoxycholate
Sir—The most compelling argument for
replacing amphotericin B deoxycholate
(AmBD) with lipid formulations of am-
photericin B (LFABs), as proposed by Os-
trosky-Zeisner et al. [1], is that it would
lead to avoidance of AmBD-associated
toxicities, among which nephrotoxicity is
the most costly and is associated with the
greatest morbidity. However, aggressive
hydration and electrolyte correction (as
noted by Ostrosky-Zeisner et al. [1] and
others [2]), as well as administration via
continuous infusion (which is not men-
tioned by Ostrosky-Zeisner et al. [1], but
which has been discussed elsewhere [3,
4]), may significantly reduce the nephro-
toxicity associated AmBD. These measures
were not systematically used in the com-
parative trials that showed a reduction in
nephrotoxicity with use of LFABs instead
of AmBD [1]. Before the much more
costly LFABs are adopted for routine use
instead of AmBD, it would seem prudent
to directly compare the nephrotoxicity of
LFABs with that of AmBD administered
in a maximally nephroprotective fashion.
With respect to the various LFABs, Os-
trosky-Zeisner et al. [1] advocate “more
head-to-head clinical trials with standard-
ized protocols of infusion and toxicity
management…to clearly define which for-
mulation is superior, if any” (p. 423). Per-
haps AmBD should be included in such
studies.
James R. Johnson
Veterans Affairs Medical Center and Department
of Medicine, University of Minnesota,
Minneapolis, Minnesota
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Continuous Infusion
of Amphotericin B
Deoxycholate: A Cost-
Effective Gold Standard
for Therapy of Invasive
Fungal Infections?
Sir—Ostrosky-Zeichner et al. [1] review
the toxicity of amphotericin B deoxycho-
late (AmBD) and recommend the newer,
very expensive lipid formulations of am-
photericin B (LFABs) as the new gold stan-
dard for therapy of invasive fungal
infections. Their main concern is nephro-
toxicity: up to 30% of patients develop
acute renal failure while receiving therapy
with AmBD, according to Bates et al. [2].
However, these investigators administered
AmBD during a 4-h period and did not
hydrate the patients appropriately.
Unfortunately, in their review, Os-
trosky-Zeichner et al. [1] did not discuss
the published studies carried out by A.
Schaffner’s research group at our institu-
tion [3–5]. Using 24-h continuous infu-
sion of AmBD in treating ∼60 severely
immunocompromised patients per year,
we observe acute renal failure very rarely.
This is because we combine antifungal
treatment with daily monitoring and ag-
gressive correction of electrolyte levels and
hydration. This observation has recently
been confirmed clinically and experimen-
tally by another research group [6]. Even
in patients receiving high doses (i.e., 11
mg/kg of AmBD in a 24-h continuous in-
fusion) or receiving concomitant treat-
ment with nephrotoxic ciclosporin A,
treatment with AmBD very rarely leads to
acute renal failure [4, 5].
Equivalent doses of LFABs are ∼10
times more expensive than doses of
AmBD. We currently save several hun-
dreds of thousands of US dollars per year
by not using LFABs. We think it is pre-
mature to establish LFABs as the gold stan-
dard for therapy of invasive fungal in-
fections. We ask for a study of cost-
effectiveness comparing equivalent doses
of the new LFABs to 24-h continuous in-
fusion of AmBD. Hospital managers and
those interested in cutting health care costs
should demand these studies before im-
plementing costly new gold-standard
therapies.
Markus Schneemann and Esther B. Bachli
Department of Medicine,
University of Zu¨rich, Switzerland
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Table 1. Data on sales of amphotericin B (AmB) formulations in the United States, 2000.
Type of AmB, brand name
Quantity
per vial,
mg
Cost
per vial,a
US$
Daily
dose,b
mg
Estimated
no. of vials
per daily dose
No. of
vials
distributedc
No. of
doses
administeredd
Estimated
sales,c US$
Estimated
cost per
dose,e US$
LFABs
Ambisome (liposomal) 50 157 350 7 808,000 115,000 … …
Abelcet (lipid-complex) 100 85 350 4 739,000 185,000 … …
50 NA 350 7 22,200 3,000 … …
Amphotec (colloidal dispersion) 100 NA 350 4 14,500 3,500 … …
50 NA 350 7 2,800 500 … …
Total … … … … 1,586,500 307,000 180,000,000 585
AmBD
Fungizone 50 4.50 35 0.7 345,500 500,000 … …
Amphotericin B 50 4.50 35 0.7 200,600 290,000 … …
Amphocin 50 4.50 35 0.7 6,500 10,000 … …
Total … … … … 552,600 800,000 3,300,000 4.50
NOTE. AmBD, amphotericin B deoxycholate; LFABs, lipid formulations of amphotericin B; NA, not available.
a Data on cost per vial provided by Jennifer Yi of Harbor-University of California Los Angeles Medical Center.
b Data assumes a mean body mass of 70 kg and a daily dose of 0.5 mg/kg per day, for AmBD, and 5 mg/kg per day, for LFABs.
c Data on no. of vials distributed and estimated sales provided by IMS Health (Fairfield, Connecticut).
d No. of doses administered is calculated by dividing the number of vials distributed by the estimated number of vials used per daily dose.
e The estimated cost per dose is calculated by dividing the estimated sales by the number of doses administered.
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Amphotericin B: Is a Lipid-
Formulation Gold Standard
Feasible?
Sir—We read with interest the article by
Ostrosky-Zeichner et al. [1] proposing
that lipid-based formulations of ampho-
tericin B (LFABs) replace amphotericin B
deoxycholate (AmBD) as the gold stan-
dard for treatment of most invasive my-
coses. On the basis of a review of com-
parative efficacy, toxicity, and cost, we
believe AmBD remains a viable first-line
agent.
Although the benefits of LFABs have
been described in relation to secondary,
microbiological end points in clinical trials
[2, 3], primary end points have not dem-
onstrated the superior efficacy of LFABs
versus AmBD. In a randomized study of
patients with histoplasmosis and AIDS,
only 1 of 3 primary end points showed an
apparent benefit of treatment with lipo-
somal amphotericin rather than with
AmBD [4]. The only outcome measure-
ment that demonstrated the superiority of
treatment with liposomal amphotericin
was “clinical success,” which was a com-
posite end point that included the require-
ment that the patient be afebrile for 3 days.
If any fever occurred during that time, in-
cluding during drug infusion, the treat-
ment was considered a clinical failure. The
apparent difference in the efficacy LFABs
and AmBD may therefore have been
caused by a difference in infusion-related
adverse events, rather than by a true dif-
ference in efficacy.
Moreover, AmBD-induced toxicities
are usually treatable (e.g., infusion reac-
tions) or reversible (e.g., anemia and az-
otemia) if treatment with the drug is dis-
continued in a timely manner [5–7].
Patients who develop toxicities can be
given an LFAB, limiting the global impact
of toxicity caused by the deoxycholate
formulation.
Finally, the cost of LFABs is prohibitive.
In the year 2000, sales of LFABs in the
United States were $180 million, versus
$3.3 million for AmBD (table 1). Indeed,
despite strictly enforced limitations on
their use at our institution, LFABs have
been the number one pharmacy cost for
each of the previous 5 years. Of the ∼1650
drugs administered to patients at Harbor-
UCLA Medical Center in 2001, LFABs ac-
counted for 5% of all pharmacy costs.
If LFABs became the new gold standard,
the financial impact would be enormous.
For example, if 75% of the doses of AmBD
administered in the United States in the
year 2000 had been administered as
LFABs, the additional cost incurred would
have been approximately $240 million
(75% of 550,000 doses  $580 in addi-
tional cost per dose). Although some of
the cost differential might be mitigated by
savings that result from a decrease in in-
